^
Association details:
| Biomarker: | FGFR3-TACC3 fusion |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) + Truseltiq (infigratinib) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations
Published date:
05/01/2020
Excerpt:
Co-treatment of infigratinib with low dose (100–200 nM) of dasatinib resulted in an almost complete elimination of the resistant colonies that were previously observed in the treatment with single agent infigratinib or dasatinib (Figure 3A,B). Notably, this effect appeared to be more potent in cells expressing FGFR3-TACC3 and the FGFR3 point mutants with some resistant colonies remaining in the WT FGFR3 expressing cells even at high drug doses.
DOI:
10.3390/ijms21093214
